| Title |
Current role of FDG PET/CT in lymphoma
|
|---|---|
| Published in |
European Journal of Nuclear Medicine and Molecular Imaging, February 2014
|
| DOI | 10.1007/s00259-013-2686-2 |
| Pubmed ID | |
| Authors |
Lale Kostakoglu, Bruce D. Cheson |
| Abstract |
The management approach in Hodgkin's (HL) and high-grade non-Hodgkin's lymphomas (NHL) has shifted towards reducing the toxicity and long-term adverse effects associated with treatment while maintaining favorable outcomes in low-risk patients. The success of an individualized treatment strategy depends largely on accurate diagnostic tests both at staging and during therapy. In this regard, positron emission tomography (PET) using fluorodeoxyglucose (FDG) with computed tomography (CT) has proved effective as a metabolic imaging tool with compelling evidence supporting its superiority over conventional modalities, particularly in staging and early evaluation of response. Eventually, this modality was integrated into the routine staging and restaging algorithm of lymphomas. This review will summarize the data on the proven and potential utility of PET/CT imaging for staging, response assessment, and restaging, describing current limitations of this imaging modality. |
Mendeley readers
The data shown below were compiled from readership statistics for 57 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 2% |
| Italy | 1 | 2% |
| Brazil | 1 | 2% |
| Denmark | 1 | 2% |
| United States | 1 | 2% |
| Unknown | 52 | 91% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 9 | 16% |
| Student > Doctoral Student | 8 | 14% |
| Researcher | 7 | 12% |
| Student > Ph. D. Student | 6 | 11% |
| Professor > Associate Professor | 6 | 11% |
| Other | 16 | 28% |
| Unknown | 5 | 9% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 40 | 70% |
| Computer Science | 2 | 4% |
| Agricultural and Biological Sciences | 2 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 4% |
| Physics and Astronomy | 2 | 4% |
| Other | 4 | 7% |
| Unknown | 5 | 9% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 February 2015.
All research outputs
#21,153,429
of 23,806,312 outputs
Outputs from European Journal of Nuclear Medicine and Molecular Imaging
#2,610
of 3,083 outputs
Outputs of similar age
#275,823
of 317,433 outputs
Outputs of similar age from European Journal of Nuclear Medicine and Molecular Imaging
#42
of 51 outputs
Altmetric has tracked 23,806,312 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,083 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.1. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 317,433 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 51 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.